Expert Interview

This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

Discussing the FDA approval of Pfizer's Abrysvo RSV maternal vaccine for the prevention of lower respiratory tract disease caused by RSV in infants from birth up to six months of age

Ticker(s): PFE

Who's the expert?

Institution: Jamaica Hospital

Associate Ob/Gyn Residency Director at Jamaica Hospital
Sees 40 patients with active and chronic VVC
Currently prescribes Brexafemme to 15 patients

Interview Goal

This interview will focus on the FDA approval of Pfizer's Abrysvo (Respiratory Syncytial Virus Vaccine) for the prevention of lower respiratory tract disease caused by RSV in infants from birth up to six months of age by active immunization of pregnant individuals at 32 through 36 weeks gestational age.

Do you want answers to these questions?

Yes! Sign me up for FREE
so I can learn more Yes.
LOGIN!

Click Here to Access
This Project

Slingshot Insights Explained

JOIN FOR FREE TODAY

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

Click Here to Access
This Project

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.